Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Real-world Study to Explore Therapeutic Changing Mode of Locally Therapy During 1L Lorlatinib Treatment in Unresectable ALK+ NSCLC Patients

NCT06690541 is registered in ClinicalTrials.gov with Peking University Cancer Hospital & Institute as lead sponsor.

NCT NCT06690541
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06690541 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Real-world Study to Explore Therapeutic Changing Mode of Locally Therapy During 1L Lorlatinib Treatment in Unresectable ALK+ NSCLC Patients
Lead sponsor
Peking University Cancer Hospital & Institute
Phase
Observational
Overall status
Not yet recruiting
Start date
November 10, 2024
Completion date
October 31, 2030
Enrollment
100 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer, non-small cell